Aarti Drugs (NSE:AARTIDRUGS) Cyclically Adjusted PB Ratio: (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AARTIDRUGS Aarti Drugs Ltd NSE:AARTIDRUGS
74 GF Score
Price ₹416.35
GF Value ₹510.25
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Aarti Drugs Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aarti Drugs  (NSE:AARTIDRUGS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Aarti Drugs Cyclically Adjusted PB Ratio Related Terms


Aarti Drugs Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Aarti Drugs's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Drugs Cyclically Adjusted PB Ratio Chart

Aarti Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.71 4.52 4.97 3.42 2.78

Aarti Drugs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 4.51 0.00 2.78 0.00

NSE:AARTIDRUGS vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Drugs Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aarti Drugs's Cyclically Adjusted PB Ratio falls into.


NSE:AARTIDRUGS
74GF Score
Aarti Drugs Ltd NSE:AARTIDRUGS
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Drugs Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Aarti Drugs's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Aarti Drugs's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Aarti Drugs Quarterly Data

Book Value per Share CPI Adj_Book
201609 41.843 105.961 66.088
201612 0.000 105.196 0.000
201703 41.930 105.196 66.707
201706 0.000 107.109 0.000
201709 45.315 109.021 69.562
201712 0.000 109.404 0.000
201803 48.281 109.786 73.599
201806 0.000 111.317 0.000
201809 52.384 115.142 76.139
201812 0.000 115.142 0.000
201903 58.310 118.202 82.559
201906 0.000 120.880 0.000
201909 61.127 123.175 83.053
201912 0.000 126.235 0.000
202003 70.010 124.705 93.955
202006 0.000 127.000 0.000
202009 87.299 130.118 112.284
202012 0.000 130.889 0.000
202103 98.007 131.771 124.475
202106 0.000 134.084 0.000
202109 100.572 135.847 123.900
202112 0.000 138.161 0.000
202203 111.918 138.822 134.923
202206 0.000 142.347 0.000
202209 119.862 144.661 138.667
202212 0.000 145.763 0.000
202303 128.773 146.865 146.741
202306 0.000 150.280 0.000
202309 131.554 151.492 145.331
202312 0.000 152.924 0.000
202403 139.397 153.035 152.443
202406 0.000 155.789 0.000
202409 139.958 157.882 148.357
202412 0.000 158.323 0.000
202503 149.994 157.552 159.329
202506 0.000 159.755 0.000
202509 160.874 162.289 165.898
202512 0.000 163.281 0.000
202603 169.701 164.272 172.888
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Aarti Drugs (NSE:AARTIDRUGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Drugs stock appears to be undervalued. The current stock price of ₹416.35 is trading 18.4% below its estimated GF Value™ of ₹510.25. GuruFocus considers Aarti Drugs to be Modestly Undervalued.

Key valuation signals for NSE:AARTIDRUGS:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹510.25 vs. price of ₹416.35 (18.4% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIDRUGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aarti Drugs Business Description

Other Exchanges 524348:India
Address Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
74GF Score

Get the complete analysis for NSE:AARTIDRUGS

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹416.35
Price
₹510.25
GF Value